Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 17 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Consun Pharma's reported carbon emissions
In 2023, Consun Pharma reported total carbon emissions of approximately 79,360,220 kg CO2e, comprising about 54,210,460 kg CO2e from Scope 1 emissions and about 24,914,760 kg CO2e from Scope 2 emissions. The Scope 1 emissions included mobile combustion, fugitive emissions, and stationary combustion, while Scope 2 emissions were primarily from purchased electricity. Over the years, Consun Pharma has seen fluctuations in its emissions, with a notable increase from about 71,151,211 kg CO2e in 2021 to the current figure. The company has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for improvement in their climate commitments. The emissions data highlights the company's reliance on fossil fuels and electricity, which are significant contributors to its carbon footprint. As the pharmaceutical industry increasingly focuses on sustainability, Consun Pharma's future climate strategies will be crucial in addressing its environmental impact and aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 735,000 | 000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 7,104,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consun Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
